Loading
A phase 3 trial of Efbemalenograstim alfa and Filgrastim in Breast cancer, run by EVIVE Biotechnology, completed.
Study to Compare the Efficacy and Safety of F-627 and GRAN® is a phase 3 interventional study registered as NCT04174599 by EVIVE Biotechnology, with 242 participants recorded, started 2018-04-12 and reaching its primary completion in 2019-01-24. Interventions recorded: F-627, GRAN®. Conditions recorded: Breast Cancer, Neutropenia.
Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
242 enrolled.
SD 1.100; Figures from the ClinicalTrials.gov results section (first posted 2025-04-20), not from a publication · SD 0.967
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1primary | F-627 | 120 | 0.68 days | - | - | link |
| GRAN® | 119 | 0.71 days |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
Shares Filgrastim (G-CSF), Breast cancer (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/